Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0000911916-17-000026)

Filing Details

Accession Number:: 0000911916-17-000026
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-01-04 16:24:22
Reporting Period:: 2017-01-03

Filing Date:: 2017-01-04
Accepted Time:: 2017-01-04 16:24:22
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1348649	Colucid Pharmaceuticals Inc.	CLCD	Pharmaceutical Preparations (2834)	203419541

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1612396	D Matthew Dallas	C/O Colucid Pharmaceuticals, Inc. 222 Third Street Cambridge MA 02142	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2017-01-03	1,473	$36.25	40,128	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Footnotes

Securities sold pursuant to a written plan intended to comply with Rule 10b5-1(c)(i) adopted by Mr. Dallas on August 15, 2016. One purpose of the plan is to sell shares of common stock acquired under the CoLucid Pharmaceuticals, Inc. Employee Stock Purchase Plan.